WO2010068130A1 - Médicament pour le traitement d'affections oncologiques utilisant un isotope de calcium 41 - Google Patents

Médicament pour le traitement d'affections oncologiques utilisant un isotope de calcium 41 Download PDF

Info

Publication number
WO2010068130A1
WO2010068130A1 PCT/RU2008/000799 RU2008000799W WO2010068130A1 WO 2010068130 A1 WO2010068130 A1 WO 2010068130A1 RU 2008000799 W RU2008000799 W RU 2008000799W WO 2010068130 A1 WO2010068130 A1 WO 2010068130A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
isotope
agent
oncological diseases
vitamin
Prior art date
Application number
PCT/RU2008/000799
Other languages
English (en)
Russian (ru)
Inventor
Василий Егорович МИЛОВ
Вячеслав Андреевич ШМАКОВ
Original Assignee
Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М""
ШМАКОВ, Андрей Вячеславович
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М"", ШМАКОВ, Андрей Вячеславович filed Critical Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М""
Publication of WO2010068130A1 publication Critical patent/WO2010068130A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the field of radiation therapy - the treatment of cancer using ionizing radiation.
  • radioactive substances 15 solid, liquid or gaseous radioactive substances or their solutions.
  • radioactive drugs used in lifepsyse are solutions of compounds labeled with radioactive isotopes.
  • the use of ionizing radiation for the treatment of malignant tumors is based on their damaging effect on cells and
  • Irradiation methods can be divided into two main groups: remote methods and contact irradiation methods.
  • remote methods With contact irradiation methods, the source is placed in close proximity to the tumor or injected directly into the tumor.
  • contact irradiation methods the source is placed in close proximity to the tumor or injected directly into the tumor.
  • a peculiar form of intratumoral exposure is the introduction
  • Radioactive phosphorus 3 2 P adsorbed mainly by reticuloendothelial and bone tissue, can be administered intravenously with multiple bone metastases.
  • Radioactive iodine 131 I selectively absorbed by thyroid tissue, is used for thyroid cancer.
  • SUBSTITUTE SHEET (RULE 26) forgotten until the end of the 1980s. With constant implantation, the sources remain in the prostate and provide radiation for several weeks or months. 125 I has a half-life of 60 days and the usually recommended minimum peripheral dose is 5,160 g per volume, which includes a prostate capsule plus 2 or 3 mm of supply. This means that 80 g is delivered in the first 60 days and the rest in a decreasing dose over the next 4-6 months (D.Ash, DM Wottomleu and BM Careu Brunswick Regiopl Septer fög Sapser Treatmpt, Soakridge Nosrtal, Leds).
  • This calcium is found in dairy products, cheese, cabbage, garlic, fish products, cereals, celery, lettuce, parsley, eggs (especially in the shell), gooseberries, currants, strawberries, cherries, legumes, etc.
  • the present invention is directed to solving the technical problem of increasing the antitumor activity of an agent for the treatment and prevention of cancer.
  • the technical result achieved in this case is to increase the effectiveness of the treatment of cancer by accumulating calcium in the body and its long-term retention.
  • the present invention contemplates a treatment modality.
  • SUBSTITUTE SHEET (RULE 26) oncological diseases using the isotope of calcium-41, which is a tablet form, which includes the following components in a weight quantity of 1 tablet:
  • the calcium-41 isotope is currently widely used in a number of scientific and clinical centers as a marker for skeletal bone damage in breast and prostate cancer (Freemap, S.R.N.T.p. M.W. apd Neapeu, RP apd Allo-wow,
  • colecalciferol (vitamin D 3 ) - 0.005-0.01 mg (200-400 ME) - provides increased absorption of calcium in the intestine, increases the permeability of cell and mitochondrial membranes of the intestinal epithelium, facilitating the transmembrane transport of calcium cations.
  • Zinc oxide - 15 mg - provides the antioxidant effect of the drug.
  • SUBSTITUTE SHEET (RULE 26) 4. calcium chloride (calcium-41) - 0.001-0.01 mg with an induced activity of 0.1 ⁇ CI - provides an antitumor effect due to the interaction of the emitted ionizing radiation with the body tissue intended for treatment. 5 5. Vitamin E - 5 mg.
  • the combined effect of the drug on the body is manifested in the antitumor effect due to the calcium isotope 41 and antioxidant effect (Ca, Zn).
  • the present invention is industrially applicable, effective in the treatment and prevention of cancer in complex treatment programs, the results of which show practical value in medicine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte au domaine de la thérapie par rayons lors du traitement d'affections oncologiques. Le médicament de traitement et de prévention des affections oncologiques se présente sous forme de cachets comprenant les composants suivants en poids pour 1 cachet : 600 à 700 mg de calcium (sous forme de carbonate de calcium); 0,005 à 0,01 mg (200 à 400 ME) de cholécalciférol (vitamine D3); 15 mg d'oxyde de zinc; de 0,001 à 0,01 mg de chlorure de calcium (calcium 41) avec une activité induite de 0,1 μKI; 5 mg de vitamine E.
PCT/RU2008/000799 2008-12-09 2008-12-25 Médicament pour le traitement d'affections oncologiques utilisant un isotope de calcium 41 WO2010068130A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2008148255/15A RU2391109C1 (ru) 2008-12-09 2008-12-09 Средство лечения онкологических заболеваний с использованием изотопа кальций-41
RU2008148255 2008-12-09

Publications (1)

Publication Number Publication Date
WO2010068130A1 true WO2010068130A1 (fr) 2010-06-17

Family

ID=42242932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2008/000799 WO2010068130A1 (fr) 2008-12-09 2008-12-25 Médicament pour le traitement d'affections oncologiques utilisant un isotope de calcium 41

Country Status (2)

Country Link
RU (1) RU2391109C1 (fr)
WO (1) WO2010068130A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183041B2 (en) 2017-04-12 2019-01-22 Vector Vitale Ip Llc Antibacterial composition and its use in treating bacterial infections
US10226484B2 (en) 2014-12-01 2019-03-12 Peter Y Novak Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
WO2022075950A1 (fr) * 2020-10-07 2022-04-14 ÖZDURAL, Ahmet Rifat Utilisation d'isotopes de calcium (ca) en tant que substances médicamenteuses actives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2141314C1 (ru) * 1998-05-12 1999-11-20 Товарищество с ограниченной ответственностью "ПАНФ" Противовирусный препарат "амиксин" и способ его получения
RU2282438C1 (ru) 2005-03-24 2006-08-27 Александра Петровна Безрукова Средство, обладающее противоопухолевой активностью
RU2324474C2 (ru) * 2001-10-23 2008-05-20 Фарматон С.А. Жевательная таблетка, содержащая лизин
RU2328294C1 (ru) * 2006-11-20 2008-07-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Росздрава Средство для профилактики рака

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2141314C1 (ru) * 1998-05-12 1999-11-20 Товарищество с ограниченной ответственностью "ПАНФ" Противовирусный препарат "амиксин" и способ его получения
RU2324474C2 (ru) * 2001-10-23 2008-05-20 Фарматон С.А. Жевательная таблетка, содержащая лизин
RU2282438C1 (ru) 2005-03-24 2006-08-27 Александра Петровна Безрукова Средство, обладающее противоопухолевой активностью
RU2328294C1 (ru) * 2006-11-20 2008-07-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Росздрава Средство для профилактики рака

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"CALCEMIN ADVANCE (CALCEMIN ADVANCE)", 13 August 2009 (2009-08-13), Retrieved from the Internet <URL:http://www.medarena.ru/doc/Vidal_Docs_Free/druginfoS_12269.asp> *
"Detecting Bone Cancer.- Lawrence Livermore National Laboratory.", CANCER S&TR, December 2006 (2006-12-01)
CHAN JM, GIOVANNUCCI EL: "Dairy products, calcium, and vitamin D and risk of prostate cancer", EPIDEMIOL REV, vol. 23, 2001, pages 87 - 92
FREEMAN, S.P.H.T., BECK, B., BIERMAN, J.M., CAFFEE, M.W., HEANEY, R.P., HOLLO-WAY, L., MARCUS, R., SOUTHON, J.R., VOGEL, J.S.: "The study of skeletal calcium metabolism with Ca-41 and Ca-45", NUCLEAR INSTRUMENTS AND METHODS IN PHYSICS RESEARCH SECTION B- BEAM INTERACTIONS WITH MATERIALS AND ATOMS, vol. 172, pages 930 - 933
GIOVANNUCCI E, RIMM EB, WOLK A, ASCHERIO A, STAMPFER MJ, COLDITZ GA ET AL.: "Calcium and fructose intake in relation to risk of prostate cancer", CANCER RES, vol. 58, 1998, pages 442 - 7
GUNNELL D, OLIVER SE, PETERS TJ, DONOVAN JL, PERSAD R, MAYNARD M ET AL.: "Are dietprostate cancer associations mediated by the TGF axis?", BR J CANCER, vol. 88, 2003, pages 1682 - 6
JENNIFER LIN, JOANN E. MANSON, DRPH, I-MIN LEE, SCD, NANCY R. COOK, JULIE E. BURING, SHUMIN M. ZHANG: "Intakes of Calcium and Vitamin D and Breast Cancer Risk in Women", ARCH INTERN MED., vol. 167, 2007, pages 1050 - 1059
LAPPE JM, TRAVERS-GUSTAFSON D, DAVIES KM, RECKER RR, HEANEY RP., VITAMIN D AND CALCIUM SUPPLEMENTATION REDUCES CANCER RISK: RESULT, AM J CLIN NUTR., vol. 85, no. 6, June 2007 (2007-06-01), pages 1586 - 91
STEM JS ET AL.: "Dietary changes favorably affect bone remodeling in older adults", J AMDIETASSOC, vol. 99, 1999, pages 1228 - 33
U. PETERS, N. CHATTERJEE, K. A. MCGLYNN, R. E. SCHOEN, T. R. CHURCH: "Calcium intake and colorectal adenoma in a US colorectal cancer early detection program", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 80, no. 5, November 2004 (2004-11-01), pages 1358 - 1365

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226484B2 (en) 2014-12-01 2019-03-12 Peter Y Novak Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
US10857180B2 (en) 2014-12-01 2020-12-08 Vector Vitale Ip Llc Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
US11484550B2 (en) 2014-12-01 2022-11-01 Vector Vitale Ip Llc Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
US12011458B2 (en) 2014-12-01 2024-06-18 Vector Vitale Ip Llc Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
US10183041B2 (en) 2017-04-12 2019-01-22 Vector Vitale Ip Llc Antibacterial composition and its use in treating bacterial infections
US11638721B2 (en) 2017-04-12 2023-05-02 Vector Vitale Ip Llc Antibacterial composition and its use in treating bacterial infections
WO2022075950A1 (fr) * 2020-10-07 2022-04-14 ÖZDURAL, Ahmet Rifat Utilisation d'isotopes de calcium (ca) en tant que substances médicamenteuses actives

Also Published As

Publication number Publication date
RU2391109C1 (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
Lawrence Nuclear physics and therapy: preliminary report on a new method for the treatment of leukemia and polycythemia
Mills The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis.
ES2268888T3 (es) El uso de radio-223 para dirigirse a tejidos calcificados para paliacion del dolor y terapia de cancer oseo.
WO2006072962A1 (fr) Ferrocyanure de calcium potassium, melange prophylactique comprenant ce compose, et leur utilisation pour provoquer le rejet de cesium radioactif chez des personnes affectees par le rayonnement nucleaire
WO2010068130A1 (fr) Médicament pour le traitement d&#39;affections oncologiques utilisant un isotope de calcium 41
Turrel et al. Techniques of afterloading iridium‐192 interstitial brachytherapy in veterinary medicine
Boz et al. Radiation therapy combined with chemotherapy for inoperable pancreatic carcinoma
CN107252437A (zh) 用于使干骺端区或小梁区的骨空腔充满钙及预防其钙流失的产品
Chen et al. Lack of the dose-rate effect of 192 Ir source activity on pelvic control and late complications after high-dose-rate brachytherapy for cervical cancer
Crabb et al. Metals and Life Chapter 9
AU2017213801B2 (en) Phosphor-containing drug activator, suspension thereof, system containing the suspension, and methods for use
Gutin et al. Combination therapy with 1, 3-bis (2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy
RU2270045C1 (ru) Способ фотон-захватной терапии опухолей
RU2191033C1 (ru) Радиофармацевтический препарат &#34;астат-211&#34; для лечения онкологических заболеваний щитовидной железы
WO2008100997A2 (fr) Procédés de traitement ou de prévention d&#39;une cystite hémorragique en utilisant un sel de glycérophosphate
JP2018529765A (ja) 癌を治療するためのグルタミン−高ｚ元素化合物
RU2211716C2 (ru) Способ лечения злокачественных опухолей носоглотки
RU2174015C1 (ru) Препарат для лечения онкологического заболевания, способ его получения и применение
Gabel Safety and efficacy in boron neutron capture therapy
Madoc-Jones et al. Clinical considerations for neutron capture therapy of brain tumors
Karaliova et al. Factors of radiation risk at radiodiagnosis and radiation therapy in healthcare institution
Nutting et al. Radiation Therapy and Soft Tissue Response
Giarola et al. Feed variation and biometrical factors in tilapias (Oreochromis niloticus) exposed to 60Co gamma radiation
US8304439B1 (en) Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
Travis et al. Late tissue changes after low dose rate total body irradiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08878780

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008878780

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 08878780

Country of ref document: EP

Kind code of ref document: A1